Evidence map›Paper›PMID 37834822›Full record

ArticleJournal of clinical medicine2023

Management and 1-Year Outcome in Elderly Patients with Hip Fracture Surgery Receiving Anticoagulation (Warfarin or DOAc) or P2Y12 Antiplatelet Agents.

Carlo Rostagno, Gaia Rubbieri, Mattia Zeppa, Alessandro Cartei, Alice Ceccofiglio, Giulio Maria Mannarino, Gualtiero Palareti, Elvira Grandone

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Carlo RostagnoDipartimento Medicina Sperimentale e Clinica, Università di Firenze, 50134 Firenze, Italy.ORCID 0000-0002-7764-8919
Gaia RubbieriMedicina Interna e Post-Chirurgica, AOU Careggi, 50134 Firenze, Italy.
Mattia ZeppaDipartimento Medicina Sperimentale e Clinica, Università di Firenze, 50134 Firenze, Italy.
Alessandro CarteiMedicina Interna e Post-Chirurgica, AOU Careggi, 50134 Firenze, Italy.
Alice CeccofiglioMedicina Interna e Post-Chirurgica, AOU Careggi, 50134 Firenze, Italy.
Giulio Maria MannarinoMedicina Interna e Post-Chirurgica, AOU Careggi, 50134 Firenze, Italy.
Gualtiero PalaretiFondazione Arianna Anticoagulazione, 40138 Bologna, Italy.
Elvira GrandoneThrombosis and Haemostasis Unit, Fondazione I.R.C.C.S. "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.ORCID 0000-0002-8980-9783
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · ITCasa Sollievo della Sofferenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Little prospective data exist regarding the perioperative management and long-term prognosis of elderly patients receiving treatment with antithrombotic drugs and undergoing urgent surgery for a hip fracture. (2) Methods: The study included patients who required hip surgery and were receiving warfarin, DOAc or P2Y12 antiplatelet agents at the moment of trauma. Ongoing antithrombotic treatment was managed according to existing recommendations. The endpoints of the study were the time to surgery, perioperative bleeding, the need for transfusion and, finally, mortality, major cardiovascular events and re-hospitalization at 6 and 12 months. (3) Results: The study included a total of 138 patients. The mean age was 86 years; 75.4% were female. Eighty-two received DOAc, thirty-six received warfarin and twenty received P2Y12 inhibitors. The controls were 283 age- and sex-matched patients who did not receive antithrombotic treatment. A total of 38% of patients receiving warfarin underwent surgery <48 h, 52% receiving DOAc, 55% receiving P2Y12 inhibitors and, finally, 82% in the control group. Perioperative bleeding and the need for transfusion were not different between the four groups. Mortality at 6 months was higher in patients receiving warfarin and P2Y12 inhibitors (30% and 25%) in comparison to DOAc and the control group (11.6% and 10%

Indexed as

DOAchip fractureP2Y12 inhibitorswarfarin

Identifiers

PMID37834822
PMCPMC10573498
OpenAlexW4387020766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.